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hepatocytes as a most critical requirement. Targeting the 
TGF-  signaling pathway has been explored to inhibit liver 
disease progression. While interfering with TGF-  signaling 
in various short-term animal models has demonstrated 
promising results, liver disease progression in humans is a 
process of decades with different phases in which TGF-  or 
its targeting may have both beneficial and adverse out-
comes. We emphasize that, in order to achieve therapeutic 
effects, targeting TGF-  signaling in the right cell type at the 
right time is required.  Copyright © 2012 S. Karger AG, Basel 
 Transforming growth factor (TGF)-  is a multiplicity 
factor mediating cellular processes, including cell growth, 
cell differentiation, apoptosis, and cellular homeostasis. 
The canonical TGF-  signaling pathway starts with 
binding of the ligand to the type II receptor, which is sub-
sequently activated by autophosphorylation and recruits 
the type I receptor ALK-5. In the next step, the type I re-
ceptor is activated by phosphorylation and this active li-
gand receptor complex then induces association of the 
intracellular signal mediators, the receptor (R)-Smad 
proteins 2 and 3. R-Smads are activated by the receptor 
complex through phosphorylation and form a complex 
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 Abstract 
 Transforming growth factor (TGF)-  is a central regulator in 
chronic liver disease, contributing to all stages of disease 
progression from initial liver injury through inflammation 
and fibrosis to cirrhosis and hepatocellular carcinoma. Liver 
damage-induced levels of active TGF-  enhance hepatocyte 
destruction and mediate hepatic stellate cell and fibroblast 
activation resulting in a wound-healing response, including 
myofibroblast generation and extracellular matrix deposi-
tion. Further evidence points to a decisive role of cytostatic 
and apoptotic functions mediated on hepatocytes, which is 
critical for the control of liver mass, with loss of TGF-  activi-
ties resulting in hyperproliferative disorders and cancer. This 
concept is based on studies that describe a bipartite role of 
TGF-  with tumor suppressor functions at early stages of liv-
er damage and regeneration, whereas during cancer pro-
gression TGF-  may turn from a tumor suppressor into a tu-
mor promoter that exacerbates invasive and metastatic be-
havior. We have delineated this molecular switch of the 
pathway from cytostatic to tumor promoting in further de-
tail and identify activation of survival signaling pathways in 
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with the common mediator (Co)-Smad4, which increases 
the retention time of the principally back and forth shut-
tling R- and Co-Smad proteins in the nucleus, thereby 
facilitating transcriptional regulation of target genes. Be-
sides this canonical signaling pathway, TGF-  is able to 
transduce its signal via a variety of other downstream 
routes. In some cell types including hepatic stellate cells 
(HSC) and hepatocytes in the liver, instead of ALK-5, 
TGF-  may also signal via the type I receptor ALK-1, 
thereby activating R-Smads 1, 5, and 8. This then leads to 
a different set of TGF-  -regulated target genes, as com-
pared to the TGF-  /ALK-5 signaling pathway. Moreover, 
the activated TGF-  receptor complex, besides the Smads, 
may use a different set of intracellular signaling media-
tors, e.g. MAP kinase signaling pathway components 
may be used from TGF-  to translate its action into the 
nucleus  [1] . This not being enough, activated R-Smad 
proteins may in addition form heteromeric complexes 
with components of other signaling pathways, e.g. with 
phosphorylated STAT3 from the JAK/STAT signaling 
pathway, thereby further increasing the repertoire of po-
tentially TGF-  -regulated target genes  [2] . Finally, R-
Smad proteins may be direct substrates of signaling path-
ways other than TGF-  , which of course induces a differ-
ent outcome in the cell. One example is the c-Jun N- 
terminal kinase (JNK) signaling cascade that mediates 
R-Smad linker phosphorylation instead of the ALK-5- 
dependent canonical C-terminal phosphorylation  [3] , 
thereby enabling a dramatic switch with regard to the cel-
lular fate as will be discussed below. 
 A third group of Smad proteins comprises the inhibi-
tory Smads, Smad6 and Smad7  [4] . Smad6 is specific for 
interference with the R-Smad1, 5, and 8 pathway, whereas 
overexpression of Smad7 in a cell completely shuts off R-
Smad-dependent TGF-  signaling very efficiently. Be-
sides this variability in TGF-  downstream signaling, a 
cohort of components have been described that may 
modulate the different steps of the signaling pathway 
from the cell surface to the nucleus, comprising, among 
other things, receptor complex formation, apical-basal 
polarity, trafficking, signaling crosstalk, binding part-
ners of R- and Co-Smad proteins, transcriptional cofac-
tors, and DNA binding partners. Taylor and Wrana  [5] 
gave an overview of those in a snapshot of the TGF-  
pathway interactome, therewith visualizing very impres-
sively the complexity of TGF-  signaling. 
 Not only due to the above, the TGF-  signaling out-
come is versatile and cell type dependent. In a given tis-
sue, TGF-  may impact nearly every cell that comes in 
contact with it. Regarding epithelia, TGF-  may induce 
cell cycle arrest, apoptosis, and adhesion, or extracellular 
matrix and cytokine production. In fibroblasts, instead, 
TGF-  induces proliferation and stimulates ECM pro-
duction and cytokine secretion. Regarding the endothe-
lium, TGF-  upregulates migration and morphogenesis 
or controls proliferation and growth, whereas in immune 
cells TGF-  is anti-inflammatory and interferes with T-
cell proliferation, NK-cell function, and antigen presen-
tation  [6] . 
 In normal liver, usually no active TGF-  is found, 
whereas upon acute damage and during chronic liver dis-
ease progression TGF-  levels are rapidly induced, con-
tinuously increasing with disease severity. This can be 
monitored in the serum of patients and therefore repre-
sents one promising and frequently used parameter for 
diagnosing liver disease in the serum of patients  [7, 8] . 
 The best studied liver cell with regard to the outcome 
of TGF-  is the HSC. In this cell type, TGF-  represents 
the most important factor for activation and myofibro-
blast transdifferentiation. If TGF-  signaling is blocked 
in stellate cells during a damage situation, myofibroblast 
generation and fibrogenesis are blunted. Typical features 
of myofibroblasts in the setting of fibrosis are upregu-
lated expression of   -smooth muscle actin (  SMA), TGF-
  , PDGF, connective tissue growth factor (CTGF), type I 
collagens, tissue inhibitor of metalloproteinase 1 (TIMP1), 
and other extracellular matrix proteins. Further features 
of HSC activation comprise gain of proliferation, migra-
tion, and contractility, along with loss of vitamin A drop-
let storage  [9] . 
 Cytostatic action of TGF-  on proliferating hepato-
cytes during liver regeneration was identified a long time 
ago. For example, Braun et al.  [10] reported already in 
1988 that TGF-  mRNA increases during liver regenera-
tion, therewith identifying a possible paracrine mecha-
nism of growth regulation. In animal models of liver re-
generation using partial hepatectomy, increased TGF-  
levels were identified shortly after proliferation peaks of 
hepatocytes and biliary ductular cells and in parallel 
with the proliferation peaks of HSC and Kupffer cells 
 [11] . Mainly from such data it is suggested that TGF-  
acts cytostatically on proliferating epithelial cells during 
liver regeneration, although the molecular details and 
downstream signaling pathways have not been investi-
gated in detail. A summary of the TGF-  role in liver 
regeneration can be found in the report by Karkampou-
na et al.  [8] . 
 When studying downstream signaling arms of the 
TGF-  pathway more thoroughly, different branches can 
be discriminated  [12] . There are on one hand the Smad-
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mediated gene responses in the nucleus, which can be 
divided into two major arms. One comprises its func-
tion as a tumor suppressor, including cytostasis (e.g. cy-
clin-dependent kinase – CDK – and c-myc inhibition), 
differentiation (e.g. ID1 regulation), and apoptosis (e.g. 
downregulation of BCL-2 and upregulation of BIM and 
GADD45  ). The other Smad-directed arm relates to ef-
fects like phenotypic plasticity (e.g. epithelial mesenchy-
mal transition inducers) and environmental components 
(e.g. extracellular matrix proteins, cytokines, and prote-
ases) or has impact on signaling pathways due to regula-
tion of receptor, signal transducer, and transcription fac-
tor expression. Besides these gene responses, there are 
also TGF-  -mediated stress responses. Here, the rela-
tions with JNK/p38, Cdc42/Rho, and Par6 were de-
scribed, which directly link TGF-  activated receptor 
complexes with an impact on cell migration, cell shape, 
and cell-cell contacts  [12] . 
 In early steps of carcinogenesis, epithelial cells may 
evade the tumor-suppressive action of TGF-  . This may 
principally be achieved via two different routes. On the 
one hand, tumor suppression can be disabled by mutation 
of pathway core components. This has been described for 
the TGF-  type I receptor, e.g. in ovary, esophagus, and 
head and neck cancer, and for the TGF-  type II receptor, 
e.g. in colon, stomach, biliary, lung, and ovarian cancer. 
Also, loss of functional Smads 2, 3, and 4 via mutation or 
genetic losses has been demonstrated in pancreatic, co-
lon, and esophagus cancer. In those cases, due to total loss 
of functional signaling components, no or only a few 
TGF-  responses remain for the cell, e.g. Smad4-inde-
pendent responses in pancreatic cancers with Smad4 
loss-of-function mutations. On the other hand, tumor 
suppression can be disabled without such loss-of-func-
tion mutations/genomic alterations by selective inhibi-
tion of the aforementioned tumor suppressor/cytostatic 
arm. This was shown, for example, in glioma due to p15/
INK4B deletion or through FoxO inhibition by Akt, or in 
breast cancer by LIP-dependent C/EBP  inhibition and/
or an ID1 switched response. In such settings, the TGF-  
signaling components are fully available, but their down-
stream signaling leading to cytostatic responses is ampu-
tated, whereby TGF-  downstream signaling is redirect-
ed towards gene responses that facilitate tumor progres-
sion and metastasis. TGF-  signaling then may lead to 
phenotypic plasticity (HMGA2, snail, and ID1 are cor-
responding signaling targets) or to the production of 
components that have a major impact on the environ-
ment (ANGPTL4, CTGF, IL1, PthRP, PDGF, and VEGF) 
 [12] .
 To delineate the switch of TGF-  effects from wound 
healing to tumor promotion during HCC development, 
one first has to understand the dynamics of histopatho-
logical progression and molecular features of HCC devel-
opment upon hepatic injury. It can be incurred by anyone 
of several factors including, among others, hepatitis B vi-
rus or hepatitis C virus infection, alcohol, and   -toxin B1, 
and upon initiation there is hepatocyte damage and ne-
crosis followed by hepatocyte proliferation and liver re-
generation. Continuous cycles of destructive and regen-
erative processes foster a chronic liver disease condition 
that culminates in liver cirrhosis. Cirrhosis is character-
ized by macroregenerative nodules that, due to increased 
proliferative activity, are surrounded by collagen deposi-
tion and scarring. In the next progression stage, hyper-
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 Fig. 1. In liver homeostasis, TGF-  provides a cytostatic signal 
mediating proliferation inhibition, apoptosis, and growth control 
(left arrow). This setting is tightly regulated by signaling path-
ways inducing cell survival. Upon cell stress and damage, e.g. me-
diated by hepatitis viral infection, drug detoxification, or others, 
survival signaling is initiated and hepatocytes are prepared to un-
dergo morphological changes, including plasticity and expression 
of stemness factors (right arrow). This abrogates the cytostatic 
TGF-  signal and redirects the pathway to a cancer-facilitating 
signature (dashed arrow). Survival and stemness signals with 
plasticity and tumorigenic TGF-  signals facilitate cancer cell 
generation and malignant progression (dotted arrow). Based on 
this model of hepatocellular carcinogenesis, we hypothesize that 
a combined therapeutic approach interfering with survival sig-
naling, e.g. inhibiting pAKT plus stimulation of cytostatic TGF-  
signaling, is promising in the early stages of malignant transfor-
mation (middle arrow and square switch). 
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plastic nodules are observed, followed by dysplastic nod-
ules and ultimately HCC, which can be further classified 
into well-differentiated, moderately differentiated, and 
poorly differentiated tumors, with the latter ones repre-
senting the most malignant form of primary HCC. Late 
disease stages include marked genomic instability and 
loss of p53 function. A summary of the different stages 
from liver damage to HCC can be found in the report by 
Farazi and DePinho  [13] .
 One molecular mechanism for how liver cells can es-
cape from the cytostatic TGF-  response was described 
by the work of Mishra and coworkers  [14–24] . Initially, 
they found that disruption of the adaptor protein ELF, a 
  -spectrin, leads to disruption of TGF-  /Smad signaling. 
Furthermore, Elf–/– mice displayed a phenotype similar 
to Smad2+/– and Smad3+/– mice with midges tational 
death due to gastrointestinal, liver, neural, and heart de-
fects. TGF-  triggers phosphorylation and association of 
ELF with Smad3 and Smad4, followed by nuclear trans-
location, therewith indicating an unexpected molecular 
link between a scaffolding protein and the TGF-  signal-
ing pathway  [24] . ELF-mediated TGF-  -dependent tran-
scriptional responses are strongly related to its cytostatic 
response, comprising, for example, induction of p15, p21, 
MMP-9, p57,   -cadherin, and p16 expression as well as 
repression of   -catenin, c-myc, hTERT, IGF2, and LDLR 
transcription  [14, 18, 20, 21] . Additionally, PRAJA, a 
RING-H2 protein, was identified to interact with ELF 
leading to enhanced degradation via substantial E3-de-
pendent ubiquitinylation. Thus, high-level expression of 
PRAJA may interfere with cytostatic TGF-  effects by re-
ducing the availability of ELF for efficient R-Smad signal 
propagation  [22] . Such data could also be validated by 
correlative immunohistochemical stainings in human 
HCC patients.
 Mishra and coworkers further pointed out that up to 
40% of hepatocellular carcinomas (HCC) are clonal and 
potentially arise from cancer stem cells (CSCs), charac-
terized by expression of stem cell markers like Oct4, 
Nanog, or Sox2, increased activation of multiple path-
ways including IL-6/STAT3, WNT, CDK4, and hedge-
hog, and a parallel loss of the TGF-  cytostatic response 
 [23] . 
 From these findings and from work with cultured 
HCC cells, it is concluded that in a setting of low ELF and 
T  RII expression or upregulated PRAJA expression, 
Smad3-mediated cytostatic TGF-  signaling is disrupt-
ed. Parallel activation of IL6, hedgehog, Notch, and Wnt 
signaling pathways will then facilitate the generation of 
CSCs that may reflect the source of HCC development. It 
is further suggested that modulating stem cell renewal 
factors such as STAT3, NANOG, and OCT4 may reduce 
HCC formation  [25] . 
 To prove the hypothesis of Mishra, we investigated ten 
different human HCC lines (manuscript in preparation). 
Measuring cytotoxicity, proliferation, Smad-binding ele-
ment reporter activation and expression of ELF and 
 PRAJA, it was obvious that Hep3B and HuH7 displayed 
a significant cytostatic response as well as Smad3/4-bind-
ing element reporter activation upon TGF-  treatment, 
accompanied by high ELF and low PRAJA expression. 
Vice versa, most of the cell lines that were not responsive 
to a cytostatic TGF-  signal had low reporter gene activa-
tion, very low ELF expression, and/or upregulated PRAJA 
expression (HCC-M, HCC-T, HepG2, and HuH6). Inter-
estingly, FLC-4 cells which had also lost the TGF-  cyto-
static response displayed quite high levels of ELF but at 
the same time strongly upregulated PRAJA expression. 
These findings in cell lines at least partially confirm a 
mechanism as described by Mishra and coworkers, indi-
cating a significant correlation of TGF-  Smad-mediated 
cytostatic signaling and ELF expression (manuscript in 
preparation).
 In another very interesting study, the Machida lab very 
impressively demonstrated the connection of hepatitis C 
virus infection, alcohol intoxication, CSC generation, 
and HCC development. Their experiments illustrated 
that HCV infection induces TLR-4 expression in hepato-
cytes, therewith sensitizing this cell type to the direct ac-
tion of lipopolysaccharides (LPS), which are available in 
increased concentrations in the blood and liver upon al-
cohol consumption. Continuous LPS-TLR4 signal trans-
duction in hepatocytes induces expression of Nanog, a 
stem cell marker, and facilitates the formation of HCC 
 [26] . In a next step, CSCs were purified from such HCC 
tumors and a liver CSC expression library was generated. 
In a functional screen using a p53-deficient CSC line and 
a soft agar colony formation assay, STAT3, YAP1, and 
Igf2bp3 were identified as proto-oncogenes in HCV/alco-
hol-mediated liver cancer. In a large series of in vivo and 
in vitro experiments, Machida and coworkers could de-
lineate the mechanism responsible for the oncogenic ac-
tivities of Nanog-dependent CSCs. Based on knowledge 
of a previous finding that YAP is able to stabilize Smad7 
 [27] , a strong inhibitor of the TGF-  /Smad signaling 
pathway, they were able to connect the oncogenic action 
of Yap1 with cytostatic TGF-  signaling. In their investi-
gation, they could show that TGF-  signaling was inter-
fered with two-fold: (i) by increasing the negative regula-
tory activity of Smad7 through YAP1 and (ii) by Igf2bp3-
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mediated activation of Akt survival signaling, which 
induces mTOR activity to interfere with Smad3-mediat-
ed TGF-  signaling. In the aforementioned setting, can-
cer cells are rather resistant to chemotherapy, e.g. rapa-
mycin has only a limited inhibitory effect on mTOR, 
whereas sorafenib-induced cell death seems to require 
functional TGF-  cytostatic signaling and is also abro-
gated in cancer cells during ongoing survival signaling. 
This was confirmed in functional experiments upon si-
lencing of YAP1 and Igf2bp3, where survival signaling in 
CSCs was blocked and cells were resensitized to cytostat-
ic TGF-  signaling. Moreover, such cancer cells were re-
sponsive for the action of rapamycin and sorafenib, which 
were able to significantly induce cell death. In conclusion, 
Machida and coworkers demonstrated a causal link be-
tween pro-oncogenic TLR-4 signaling and a defective 
TGF-  tumor suppressor pathway, which is mediated by 
the TLR-4/Nanog target genes Yap1 and Igf2bp3 (pers. 
commun.; manuscript in preparation, and a report by 
Machida et al.  [28] ). 
 In our studies with HCC cell lines, we could also find 
supportive data for this study. We found a negative 
 correlation between intrinsic Smad7 expression and the 
duration of Smad2 activation. Cell lines with low Smad7 
expression display a prolonged phosphorylated (p) Smad2 
signal as compared to such cell lines with high intrinsic 
Smad7 expression, which have only a transient upregula-
tion and subsequent degradation of pSmad2. On the oth-
er hand, Smad7 expression was nicely correlated with 
TGF-  expression of the respective cell lines. Given that 
TGF-  may induce Smad7 expression, the identified pro-
file may reflect autocrine TGF-  effects. The most sig-
nificant support for the notion that Smad7 overexpres-
sion may indeed participate in liver carcinogenesis came 
from studying Smad7 mRNA expression in 146 matched 
HCC/normal liver tissue samples, where 65.8% displayed 
Smad7 overexpression in cancer cells (manuscript in 
preparation). To obtain further insight into the role of 
TGF-  /Smad7 in liver cancer, we are currently investigat-
ing mouse strains with hepatocyte-specific and inducible 
Smad7 overexpression/knockout in a model of liver can-
cer using DEN treatment and we are investigating strains 
generated by crossing those animal models with FAH–/– 
mice, which spontaneously develop HCC.
 The lab of Matsuzaki identified an important molecu-
lar switch mechanism from TGF-  cytostatic towards fi-
brogenic/carcinogenic action that is directly linked to 
biochemical modulations of Smad2 and Smad3. They 
could show that the canonical signaling pathway com-
prising binding of TGF-  to T  RII/ALK5 leads to direct 
phosphorylation of the C-terminus of Smad3 (pSmad3C) 
in hepatocytes, which subsequently inhibits hepato-
cyte proliferation by upregulating p21 WAF1 transcription. 
Stress situations towards hepatocytes, e.g. hepatitis virus 
infections, pro-inflammatory cytokines, alcohol, drug 
intoxication, and somatic mutations, can transmit mito-
genic signals, among others, through the JNK-dependent 
signaling pathway. Activated JNK is able to phosphory-
late Smad3 at the linker region (pSmad3L) and thus initi-
ates the pSmad3L pathway leading to hepatocyte prolif-
eration, possibly by stimulating transcription of the c-
Myc gene. Additionally, linker phosphorylation of Smad3 
indirectly prevents Smad3 C-terminal phosphorylation, 
pSmad3C-mediated p21 WAF1 transcription, and conse-
quently the cytostatic effect of TGF-  in normal hepato-
cytes. Either various JNK inhibitors or a Smad3 mutant 
lacking the JNK phosphorylation site in the linker region 
can eliminate mitogenic pSmad3L signaling and there-
with restore the loss of pSmad3C signaling observed in 
normal hepatocytes  [29–31] . On the other hand, collagen 
synthesis by mesenchymal cells including fibroblasts, 
mesangial cells, and HSC appears to be promoted by the 
dually phosphorylated Smad2 (pSmad2L/C) pathway. 
Thus, linker phosphorylation of Smad3 antagonizes its 
C-terminal phosphorylation, but linker and C-terminal 
phosphorylation of Smad2 act synergistically in driving 
fibrogenesis. In patients with HCV-related chronic liver 
diseases, chronic inflammation shifts hepatocytic pSmad 
signaling from tumor-suppressive pSmad3C to carcino-
genic pSmad3L and fibrogenic pSmad2L/C branches, 
which accelerates liver fibrosis and increases the risk of 
HCC. Chronic inflammation caused by HCV infection 
thereby represents an early fibro-carcinogenic step, pro-
viding a nonmutagenic tumor-promoting stimulus. In 
advanced fibrotic livers, mitogenic, genetic, or epigenet-
ic alterations drive multi-step fibro-carcinogenesis. Pa-
tients with mild fibrosis respond effectively to anti-viral 
therapy. According to the hypothesis of Matsuzaki, this 
is at least partially based on successful switching of 
 pSmad signaling from carcinogenic pSmad3L and fibro-
genic pSmad2L/C to tumor-suppressive pSmad3C. That 
means that if patients achieve anti-viral treatment before 
hepatocytes have acquired oncogenic potential, HCV 
clearance interferes with fibrosis and reduces HCC inci-
dence. However, HCC develops particularly in patients 
with advanced liver fibrosis, where an inflammation-in-
dependent process of fibro-carcinogenesis, possibly now 
driven by genetic and epigenetic alteration, has already 
begun before HCV clearance (manuscript in prepara-
tion). In this setting, a backswitch of TGF-  /Smad sig-
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naling from fibro-carcinogenic to cytostatic cannot be 
achieved due to passage across a ‘point of no return’  [32–
34] .
 The lab of Mikulits has also intensely investigated the 
transformation of hepatocytes into cancer cells with a
focus on the TGF-  signaling pathway. Many of their 
studies were performed with hepatocytes isolated from 
p19(ARF)–/– mice. Loss of p19(ARF) lowers the growth-
suppressive functions of p53 and bypasses cellular se-
nescence without loss of genetic stability. Thus, it was 
possible to generate immortalized murine hepatocytes, 
which display a high degree of differentiation and display 
arrest in the G1 phase under exposure to TGF-  . These 
hepatocytes maintain epithelial polarization upon ex-
pression of oncogenic Ha-Ras. However, Ras-transformed 
hepatocytes rapidly convert to a spindle-shaped, fibro-
blastoid morphology upon treatment with TGF-  , which 
no longer inhibits proliferation  [35] . In further studies, 
the lab of Mikulits showed that loss of E-cadherin, in-
creased LEF/TCF-  -catenin, as well as PDGF signaling 
and c-Fos cooperate with autocrine TGF-  signaling to 
maintain an undifferentiated mesenchymal ‘hepatocyte’ 
phenotype  [36–40] . In addition, the role of TGF-  in cell-
cell communication between HCC cells and intra-/peri-
tumorally accumulated, activated HSC-derived, stroma 
myofibroblasts was investigated. By employing cellular 
transplantation, interaction of neoplastic hepatocytes 
with the tumor microenvironment containing activated 
HSC or myofibroblasts derived thereof induces increased 
nuclear localization of Smad2/3 and   -catenin, thereby 
facilitating malignant progression. Interference with 
TGF-  signaling by Smad7 expression in hepatocytes di-
minished nuclear   -catenin, epithelial dedifferentiation, 
and tumor progression, indicating a crosstalk between 
TGF-  and   -catenin signaling. The authors conclude 
that HSC-derived myofibroblasts directly govern hepato-
carcinogenesis in a TGF-  -dependent fashion by induc-
ing autocrine TGF-  signaling and nuclear   -catenin ac-
cumulation in neoplastic hepatocytes. Similar results 
monitoring the invasive behavior of malignant cells were 
obtained in collagen gel-based three-dimensional micro-
organoid HCC spheroids; it was significantly diminished 
after inhibition of TGF-  or PDGF signaling. The au-
thors conclude that the TGF-  /PDGF/  -catenin axis in 
malignant hepatocytes is triggered from hepatic tumor-
stroma crosstalk and is crucial for both tumor growth 
and cancer progression  [41–43] .
 Giannelli et al.  [44] showed that TGF-  stimulates   3-
integrin expression in malignant hepatocytes, which 
triggers their transformation into a motile and invasive 
phenotype. In HCC patients, TGF-  1 serum concentra-
tions and   3-integrin expression are strongly correlated 
 [44] . They further showed that in HCC of human pa-
tients, Ln-5, Snail, and Slug are upregulated, E-cadherin 
is downregulated, and   -catenin is translocated into the 
nuclei. In vitro, Ln-5 mediates partial EMT, upregulation 
of Snail and Slug, and downregulation of E-cadherin in 
HCC ‘invasive’ cells which, however, do not scatter. In the 
presence of both Ln-5 and TGF-  , the EMT process is 
completed,   -catenin is translocated into the nuclei, and 
cells scatter and become invasive. The process can be re-
versed by anti-  3 integrin blocking antibody  [45] .
 Human HCC cell lines were treated with an ALK-
5 inhibitor (LY2109761), which selectively blocks TGF-
  -induced pSmad2 and dephosphorylates autocrine 
 pSmad2 at concentrations ranging from 0.001 to 0.1   M . 
The drug upregulates E-cadherin mRNA and protein lev-
els, inhibits migration on fibronectin, laminin-5, and vi-
tronectin, and abrogates invasion through Matrigel. Fur-
thermore, nonmetastatic HCC tissues from 7 patients 
were cultured with TGF-  in the presence or absence of 
LY2109761. E-cadherin expression was reduced by TGF-
  and was significantly increased upon LY2109761 treat-
ment, as measured by quantitative real-time PCR on mi-
crodissected tissues and by immunohistochemistry on 
serial sections. In 72 patients, E-cadherin tissue expres-
sion was more weakly expressed in metastatic HCC than 
in nonmetastatic HCC  [46] .
 In another study, the Giannelli lab showed that HCC 
cells invade blood vessels via   5  1-integrin, which, how-
ever, is equally expressed in invasive and noninvasive 
cells and requires phosphorylation of the intracytoplas-
mic tail at threonine 788–789. This is achieved by TGF-  
via Smad2 and Smad3, thereby modulating noninvasive 
HCC cells to behave like invasive cells. An ALK-5 inhib-
itor efficiently interferes with   5  1-integrin phosphory-
lation and blocks invasion of HCC cells. This mechanism 
was confirmed in human HCC patients with microvas-
cular invasion that displayed p  5  1-integrin, TGF-  1, 
pSmad2, and E-cadherin, indicating that TGF-  1 pro-
motes vascular invasion by activating   5  1-integrin 
 [47] . 
 Further, Giannelli and coworkers showed that treat-
ment of HCC with the ALK-5 inhibitor LY2109761 inhib-
its molecular pathways involved in neo-angiogenesis and 
tumor growth. Interestingly, this anti-angiogenic effect is 
more effective than that of bevacizumab, which specifi-
cally targets VEGF. Mechanistically, LY210976 disrupted 
the paracrine crosstalk between HCC and endothelial 
cells that involved Smad2/3-mediated signaling and af-
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fected the secretion of VEGF, thus inhibiting blood vessel 
formation  [48] .
 Finally, the Giannelli group took into account tumor-
stroma interactions and showed that HCC invasive cells 
produce high levels of CTGF and generate tumors with a 
high stromal component in a xenograft model. LY2109761 
treatment inhibited the synthesis and release of CTGF 
from malignant hepatocytes and reduced the stromal 
component of the tumors. Furthermore, the decrease in 
CTGF production diminished tumor growth, intravasa-
tion, and metastatic dissemination of HCC cells by in-
hibiting cancer-associated fibroblast proliferation. More-
over, TGF-  treatment was able to enhance CTGF pro-
duction in noninvasive HCC cells, which subsequently 
form tumors with a high stromal content, acquired in-
travasation, and metastatic spread, all of which could be 
blunted by treatment with LY2109761  [49] . 
 Taken together, preclinical results from the Giannelli 
lab indicate that the TGF-  /ALK-5 inhibitor LY2109761 
targets the crosstalk between HCC, stroma myofibro-
blast, and vascular endothelial cells with a strong impact 
against tumor progression and malignancy, thus provid-
ing a rationale for future clinical trials. 
 A very impressive clinical study was performed in the 
Thorgeirsson lab by Coulouarn et al.  [50] . Taking into ac-
count the clinical heterogeneity of HCC and the highly 
variable clinical course of HCC patients, they assumed 
that biological subgrouping could provide a better mo-
lecular classification of HCC useful for prognostic pre-
dictions and to select treatment options. Based on the 
knowledge of TGF-  as a potential provider of both tu-
mor-suppressive (growth inhibition, apoptosis) and on-
cogenic (EMT, invasiveness, etc.) properties, they select-
ed TGF-  gene expression signatures in such an approach 
to refine the classification and prognostic predictions for 
HCC patients. Therefore, Coulouarn et al.  [50] first estab-
lished a temporal TGF-  gene expression signature in 
mouse hepatocytes. Applying then a comparative func-
tional genomics approach comprising 139 HCC patients, 
they were able to successfully discriminate distinct sub-
groups of HCC. The TGF-  -positive cluster included two 
novel homogeneous groups of HCC associated with early 
and late TGF-  signatures. Kaplan-Meier plots and log-
rank statistics indicated that the patients with a late TGF-
  signature showed significantly shortened mean surviv-
al times (16.2  8 5.3 months) compared to the patients 
with an early (60.7  8 16.1 months) TGF-  signature. 
 In a similar approach, the authors had previously sub-
classified the same HCC patients as having either bad or 
good prognoses with regard to survival, hepatocytes ver-
sus hepatoblasts, and HGF/c-Met positive versus negative 
gene expression signatures. With the addition of early 
and late TGF-  signatures into these profiles, hepato-
blast-HGF/c-Met positive/late TGF-  signatures could
be correlated with the worst patient outcome.
 Also, tumors expressing late TGF-  responsive genes 
displayed an invasive phenotype and increased tumor re-
currence. Furthermore, a late TGF-  signature was able 
to accurately predict liver metastasis and discriminated 
HCC cell lines by degree of invasiveness. 
 In the group of Dooley, two different culture setups for 
primary mouse hepatocytes are in use, i.e. a collagen 
sandwich or a collagen monolayer, as previously reported 
 [51] . In the collagen sandwich, hepatocytes maintain po-
larity and are able to form bile canaliculi for up to 2 weeks, 
therewith conserving hepatocyte physiological functions 
to a relatively large extent. In collagen monolayer cul-
tures, hepatocytes lose their orientation and polarity. In 
this setting, especially mouse hepatocytes rapidly display 
a stress response, either inducing a survival program with 
gain of plasticity and transdifferentiation into cells with 
myofibroblast features or alternatively entering apopto-
sis. The collagen monolayer induces focal adhesion ki-
nase (FAK) via Src, which leads to activation of AKT and 
extracellular signal-regulated kinase (ERK) 1/2 path-
ways. AKT causes resistance to TGF-  -induced apopto-
sis by antagonizing p38, whereas ERK1/2 signaling opens 
the route to EMT. 
 In contrast to the collagen monolayer, in the collagen 
sandwich FAK activation does not occur, keeping the he-
patocytes in a state where they remain sensitive to TGF-
  -induced apoptosis and do not undergo EMT. In this 
culture system, inhibition of p38 as well as overexpression 
of constitutively active AKT causes apoptosis resistance, 
whereas constitutively active Ras induces EMT. Interest-
ingly, matrix-induced EMT can be reversed by replating 
cells from the collagen monolayer into the collagen sand-
wich system, indicating that hepatocyte dedifferentiation 
in vitro is an active process driven by FAK-mediated AKT 
and ERK1/2 signaling  [51] . 
 In addition, hepatocytes cultured on a collagen mono-
layer display a high basal frequency of proliferation. In 
order to identify the mechanisms initiating hepatocyte 
‘plasticity’ and priming for proliferation in further detail, 
gene expression patterns were investigated and genes re-
lated to MAPK signaling and the cell cycle were found to 
be upregulated, with the latter having an overrepresenta-
tion of transcription factor binding sites for ETF (TEA 
domain family member 2), E2F1 (E2F transcription fac-
tor 1), and SP-1 (Sp1 transcription factor), all depending 
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on MAPK signaling. ERK1/2 phosphorylation was iden-
tified as an early event, accompanied by proliferative ac-
tivity, as measured by bromodeoxyuridine labeling. The 
MEK inhibitor PD98059 blunted these effects, indicating 
MAPK signaling as a major trigger for the hepatocyte 
proliferative response. Furthermore, hepatocytes with 
pERK1/2 staining and nuclear SP-1 and E2F1 expression 
were found in liver tissue of mice challenged with CCl4, 
confirming that hepatocytes cultured as a collagen mono-
layer are primed for proliferation through activation of 
MAPK signaling that induces a proliferative expression 
signature via transcription factors ETF, E2F1, and SP-1 
 [52] .
 Human and rat hepatocytes are more stable when cul-
tured in the collagen monolayer system and keep polarity 
for about a week, whereas mouse hepatocytes display this 
stress response already at day 2 in culture. 
 Interestingly, stressed hepatocytes resist cytostatic 
TGF-  signaling without decreasing responsiveness, e.g. 
measured as TGF-  -mediated Smad activation. Instead, 
the TGF-  pathway further facilitates and enhances
the aforementioned transdifferentiation process. That is 
achieved by a caveolin-1-dependent non-Smad signaling-
mediated increase in pAKT  [53] and a Smad-dependent 
gene expression profile that reflects the aforementioned 
late TGF-  signature  [50] , including, among others, up-
regulation of vimentin, Snail, Slug, VEGF, CTGF, TGF-  , 
TIMP-1, PDGF, Col1A1/2, PAI-1, TSP-1, N-cadherin, and 
phalloidin and downregulation of E-cadherin, ZO-1, and 
claudin-1. All of these Smad-mediated effects can be 
blunted by ectopic or transgenic expression of Smad7 in 
vitro and in vivo  [54] . 
 This further supports the role of TGF-  as: (i) an in-
ducer of EMT and (ii) a producer of secretory proteins for 
tumor cell/stroma communication in malignant hepato-
cytes. Especially the fact that these tumorigenic TGF-  
actions may be redirected to cytostasis just by interfering 
with AKT signaling might be of high pharmaceutical in-
terest. 
 In summary, HCC can be characterized as a cancer 
type in which activation of the TGF-  signaling pathway 
is not disrupted and plays a major role in tumor progres-
sion to malignancy. The tumor-promoting action of 
TGF-  is achieved by selective inhibition of the tumor 
suppressor arm early in malignant transformation that 
involves several molecular mechanisms. Importantly,
in this scenario the TGF-  signal is redirected towards 
tumor progression and malignancy via expression sig-
natures mediating hepatocyte plasticity and EMT and 
encoding secreted proteins that act on the tumor envi-
ronment. Interestingly, in early transformed stages tu-
morigenic TGF-  signaling can be reverted to cytostatic 
by interfering with survival signaling, which may have an 
important impact on the development of therapeutic ap-
proaches aiming to interfere with liver carcinogenesis. 
This is schematically summarized in  figure 1 .
 Since molecular targeting of the TGF-  pathway is ex-
perimentally well established and is currently being test-
ed in a clinical study to treat patients with progressed 
HCC, the above data additionally advise that a combined 
approach comprising interference with survival signal-
ing plus activation of TGF-  signaling may induce HCC 
cell death and may thus be efficient in the early stages of 
HCC development. 
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